New & Notable
5 notable pharma CEO pay hikes in 2025
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”
— PharmaVoice
OpenAI debuts AI model GPT-Rosalind to speed up drug discovery
Biopharma companies, including Moderna and Amgen, are working with OpenAI to integrate its new artificial intelligence model into their workflows to accelerate research and discovery.
Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director
If confirmed by the Senate, Schwartz could finally fill a void for an agency that’s cycled through multiple leaders over the last year.
— BioPharma Dive
FDA moves toward easing restrictions on certain peptides
The agency’s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he’s a “big fan” of peptides.
— BioPharma DiveLilly boosts ADC portfolio with CrossBridge Bio deal
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform
With the addition of AbbVie and Genentech this week, the number of Big Pharma companies now offering certain branded medications on TrumpRx has grown to 11.
-
Drug manufacturing deals move to Europe despite pharma tariffs
Last year marked the sharpest decline in U.S. contract manufacturing deals for FDA-approved drugs in half a decade, despite Trump's push for domestic onshoring, GlobalData finds.
-
Novo claims edge over Lilly's newly approved GLP-1 pill in cross study
Novo Nordisk is claiming the upper hand over Eli Lilly in the oral weight-loss drug market, saying its oral Wegovy topped Lilly's recently approved GLP-1 pill in a cross-trial comparison.
-
Eli Lilly expands Insilico pact with $2.75B AI drug discovery deal
The expanded partnership gives Lilly global rights to Insilico Medicine's preclinical oral therapies, deepening its push into AI-driven R&D.
-
GLP-1 drugs show promise in managing chronic migraines
Chronic migraine patients taking GLP-1s are associated with fewer ER visits, hospitalizations and treatment interventions than those taking a common first-line migraine drug, a study shows.
-
Boehringer Ingelheim adds 3 drugs to TrumpRx
Boehringer Ingelheim is the latest drugmaker to make good on its TrumpRx deal with the White House, expanding the self-pay platform's offerings by three more medications.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.